Exosome Diagnostics is a biotech company focused on developing and commercializing revolutionary, biofluid-based diagnostics to deliver personalized precision healthcare that improves lives.
Exosome Diagnostics – biofluid-based diagnostics
Exosome Diagnostics harnesses the power of exosomes, important cell messengers carried within biofluids, such as serum, plasma, urine, cerebrospinal fluid and saliva. Exosomes contain RNA, DNA and proteins from their cell of origin. Interestingly, molecular mutations in a tumor could be detected in RNA extracted from exosomes and this information could be used diagnostically. Exosome Diagnostics’ proprietary exosome-based technology can harvest the rich and comprehensive molecular information contained within exosomes from any biofluid, fresh or frozen, without requiring the use of tissue. Highly robust and versatile, this technology holds the potential to deliver on the promise of personalized healthcare to guide treatment decisions precisely and in real-time along the entire patient care continuum. Exosome Diagnostics is developing breakthrough exosome-based diagnostics that can combine RNA analysis with DNA and protein analysis to deliver comprehensive and dynamic molecular insights. These diagnostics are poised to radically transform how cancer and other serious diseases are detected, diagnosed, treated and monitored.
Exosome Diagnostics is the leader in harnessing the power of exosomes and other microvesicles to develop diagnostics that can be used to help better inform the diagnosis, detection, treatment and monitoring of cancer and other serious diseases. Exosome Diagnostics will be the first company to commercialize exosome-based diagnostics in 2015. Exosome Diagnostics is also collaborating with pharma companies to help them enhance the R&D process, from biomarker discovery through validation, and the development of sophisticated companion diagnostics (CDx).
Exosome Diagnostics is a biopharma company headquarted in the USA. Management Team is composed by Thomas McLain, Johan Skog, William Kelly, Vincent O’Neill and Mikkel Noerholm. And Board of Directors is composed by Kapil Dhingra, Joseph Boystak, Peter Johann, Thomas McLain, Geert-Jan Mulder, Joseph Slattery and Steven Soignet.
More about Exosome Diagnostics : www.exosomedx.com